109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
索尼德吉布治疗伴有系统性红斑狼疮的基底细胞癌的经验：一例报告
Authors Shi L , Liu B , Gao P, Cao X, Wan C
Received 2 August 2025
Accepted for publication 30 October 2025
Published 21 November 2025 Volume 2025:18 Pages 3127—3132
DOI https://doi.org/10.2147/CCID.S555755
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Michela Starace
Liangliang Shi,1,* Binxin Liu,1,* Pengxiang Gao,2 Xianwei Cao,1 Chuan Wan1
1Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chuan Wan, Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China, Email chuanwan@ncu.edu.cn
Abstract: Basal Cell Carcinoma (BCC), a prevalent skin cancer originating from keratinocytes, is mainly caused by the malfunctioning of the Hedgehog (Hh) signaling pathway. Surgical removal stands as the primary treatment, while non-invasive remedies encompass treatments like topical drug therapy, photodynamic therapy, radiotherapy, and molecular biologics, among others. For patients with locally advanced or metastatic basal cell carcinoma, agents targeting the Hedgehog signaling pathway, like sonidegib, have received approval, especially in cases where the lesion is inoperable or unsuitable for radiotherapy. Lupus erythematosus (LE), an autoimmune disorder, may include skin symptoms (such as discoid lupus erythematosus, DLE) and various systemic forms. Presently, there’s a lack of documented clinical use of sonidegib in BCC patients alongside LE, particularly due to its unclear immunomodulatory impact on existing autoimmune diseases. In this report, we present a case involving a BCC patient and systemic lupus erythematosus (SLE), who received sonidegib treatment yielding positive results without simultaneously triggering lupus erythematosus activity.
Keywords: basal cell carcinoma, systemic lupus erythematosus, sonidegib, targeted therapy, immune
1Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chuan Wan, Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China, Email chuanwan@ncu.edu.cn
Abstract: Basal Cell Carcinoma (BCC), a prevalent skin cancer originating from keratinocytes, is mainly caused by the malfunctioning of the Hedgehog (Hh) signaling pathway. Surgical removal stands as the primary treatment, while non-invasive remedies encompass treatments like topical drug therapy, photodynamic therapy, radiotherapy, and molecular biologics, among others. For patients with locally advanced or metastatic basal cell carcinoma, agents targeting the Hedgehog signaling pathway, like sonidegib, have received approval, especially in cases where the lesion is inoperable or unsuitable for radiotherapy. Lupus erythematosus (LE), an autoimmune disorder, may include skin symptoms (such as discoid lupus erythematosus, DLE) and various systemic forms. Presently, there’s a lack of documented clinical use of sonidegib in BCC patients alongside LE, particularly due to its unclear immunomodulatory impact on existing autoimmune diseases. In this report, we present a case involving a BCC patient and systemic lupus erythematosus (SLE), who received sonidegib treatment yielding positive results without simultaneously triggering lupus erythematosus activity.
Keywords: basal cell carcinoma, systemic lupus erythematosus, sonidegib, targeted therapy, immune